经房间隔入路植入经导管心脏瓣膜治疗重度二尖瓣环钙化
OBJECTIVE: To assess the outcomes of transatrial implantation of a transcatheter heart valve (THV) for the treatment of mitral valve disease with severe mitral annular calcification (MAC).…
要点
- 重度二尖瓣环钙化外科高危患者经房间隔植入经导管瓣膜技术成功率高。
- 术后平均跨二尖瓣压差由10±5降至4±2 mm Hg,全部患者仅微量或轻度反流。
- 住院死亡5例(19%),30天全因死亡率27%,合并慢性肾病需多瓣膜手术者风险似更高。
核心结论
- 经房间隔植入经导管心脏瓣膜治疗二尖瓣环钙化尽管解剖条件不利,技术成功率高;在此早期经验中,外科极高危患者30天全因死亡率高。
- 作者认为风险特别高的患者似乎是需要多瓣膜手术的慢性肾病患者。
研究设计与样本
- 多中心病例系列,纳入6个中心连续26例有症状的重度二尖瓣环钙化患者,平均年龄78±7岁,92%为女性,平均胸外科医师协会(STS)评分9.4±4.8。
- 在体外循环下经左心房显露植入球囊扩张式经导管心脏瓣膜,系统性切除二尖瓣前叶并放置带垫片缝线以增强稳定性、减少瓣周漏。
主要发现
- 2例(8%)植入Edwards Sapien XT,24例(92%)植入Edwards Sapien 3生物瓣;11例同期行主动脉瓣置换。
- 按二尖瓣学术研究联盟(MVARC)标准,全部患者技术成功。
- 平均跨二尖瓣压差由10±5降至4±2 mm Hg(P<.001),全部患者仅微量或轻度反流。
- 1例(4%)观察到平均跨主动脉压差升高(30 mm Hg)。
- 住院期间死亡5例(19%),出院至30天再死亡2例(30天死亡率27%);其余患者持续功能改善。
关键数值与推荐
- 技术成功按二尖瓣学术研究联盟(MVARC)标准判定,全部患者达到。
- 平均跨二尖瓣压差由10±5降至4±2 mm Hg(P<.001)。
- 30天全因死亡率为27%(住院死亡5例,占19%;出院至30天再死亡2例)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the outcomes of transatrial implantation of a transcatheter heart valve (THV) for the treatment of mitral valve disease with severe mitral annular calcification (MAC). METHODS: Implantation of a balloon-expandable THV was performed on cardiopulmonary bypass via left atrial exposure in patients considered at risk for left ventricular outflow tract obstruction. The anterior mitral valve leaflet was systematically resected and pledgeted sutures were placed to enhance stability and reduce paravalvular leak. RESULTS: Twenty-six consecutive symptomatic patients with severe MAC (mean age, 78 ± 7 years; 92% female; mean Society of Thoracic Surgeons score, 9.4 ± 4.8) were included at 6 different centers. Two patients (8%) received an Edwards Sapien XT (Edwards Lifesciences, Irvine, Calif), and 24 (92%) an Edwards Sapien 3 bioprosthesis (Edwards Lifesciences). Concomitant aortic valve replacement was performed in 11 patients. Technical success according to the criteria of the Mitral Valve Academic Research Consortium was achieved in all patients. The mean transmitral gradient decreased from 10 ± 5 to 4 ± 2 mm Hg (P < .001) with trace or mild regurgitation in all patients. An elevated mean transaortic gradient (30 mm Hg) was observed in 1 patient (4%). Five patients died during hospital stay (19%) and 2 additional between discharge and 30 days (30-day mortality: 27%). Sustained functional improvement was observed in the remaining patients. CONCLUSIONS: Transatrial implantation of a THV for the treatment of MAC is associated with high technical success despite unfavorable anatomy. In this early experience of very high surgical risk patients, 30-day all-cause mortality was high. Patients at particular risk appear to be those with chronic kidney disease requiring multiple valve surgery.
引用
- Praz F, Khalique OK, Lee R, et al. Transatrial implantation of a transcatheter heart valve for severe mitral annular calcification. J Thorac Cardiovasc Surg. 2018. PMID: 29627180. doi:10.1016/j.jtcvs.2018.03.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。